Searched for
RADIOPHARMA
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...- Jubilant Group promoters to offload stakes in listed companies via block deals: ReportJubilant Group stake sale: The Bhartia family plans to offload stakes in Jubilant FoodWorks, Pharmova, and Ingrevia via block deals. The mo...
- Jubilant promoters eye Rs 2,000 crore via stake sales for Hindustan Coca-Cola Beverages dealJubilant Bhartia Group's promoters are selling minority stakes in listed companies to raise ₹2,000 crore for partially funding the acquisit...
- Stocks in news: IDBI Bank, Suzlon Energy, RIL, HDFC Bank, Kotak Bank, JSW SteelProfit booking causes dip in equity indices after rally. IDBI Bank, Suzlon Energy, RIL, HDFC Bank, Kotak Mahindra Bank, and JSW Steel in fo...
- Jubilant Pharmova's US arm prepays Rs 626 crore term loanJubilant Pharmova's US subsidiary secured a $75 million term loan, as of March 31, 2024, the company's gross debt stood at Rs. 3,414 crore ...
- Jubilant Pharmova shares jump over 6% on receiving USFDA approval for Technetium Sulfur Colloid InjectionFor this approval, Jubilant is eligible for 180 days of exclusivity through the ‘Competitive Generic Therapy’ designation from the US FDA.
- Why this Jhunjhunwala stock is seeing rating downgradesA few analysts believe revenues have bottomed out for drug maker Jubilant Pharmova, others do not hold high hopes in the short term
- Jubilant Pharmova Q2 net dips 3% to Rs 143 croreConsolidated total revenue from operations stood at Rs 1,657.45 crore in the second quarter as against Rs 1,591.35 crore in the year-ago pe...
- Buy Jubilant Pharmova, target price Rs 920: Motilal OswalJubilant Pharmova Ltd., incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 11241.27 Crore) operating in Pharmac...
- Buy Jubilant Pharmova, target price Rs 960: Motilal OswalJubilant Pharmova Ltd., incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 12593.56 Crore) operating in Pharmac...
- Jubilant Pharmova posts Rs 214 cr profit in Q4Sales stood at Rs 1,552 crore for the fourth quarter while the same was at Rs 1,497 crore in the same period of FY20.
- Jubilant Life Sciences Q3 net profit down 24% to Rs 203.38 croreNet sales during the quarter under review stood at Rs 2,279.89 crore, down 3.11 per cent.
- Buy Jubilant Life Sciences, target Rs 710: ICICI DirectJubilant Life Sciences is a midcap company, operating in pharmaceuticals and health care sector.
- 10 midcaps creating buzz after strong Q3 performance; brokerages increase target pricesThe action in the domestic stock market has become stock-specific with shares of several midcaps with strong Q3 numbers rallying beyond ana...
- Outperform Jubilant Life Sciences Ltd., target Rs 590.0 : Macquarie Capital SecuritiesThe speciality sales (CMO / Radiopharma) are the biggest margin lever for the company. The pharma business provides much-needed stability t...
- Buy Jubilant Life Sciences Ltd., target Rs 555.0 : Systematix Shares & StockSystematix estimates revenue and profit CAGR of ~8% and ~26% respectively over FY16-18e.
- Jubilant Life to consolidate pharma business under Singapore unitThe company's board has approved a proposal to transfer its active pharmaceutical ingredient and dosage form business to its Singapore-base...
- CRAM sector has been growing at 15-20%: Jubilant OrganosysHari Bhartia, co-chairman & managing director, Jubilant Organosys, in a chat with ET Now talks about the CRAM sector.
- Siemens to make nuclear medicines at Indian plantsGermany’s Siemens AG is finalising plans to manufacture radiopharmaceuticals (nuclear medicines) in India.
- Religare assigns 'buy' to Jubilant on Draxis buy; target Rs 405The acquisition of Canada-based Draxis Health is expected to enhance Jubilant Organosys’ presence in the regulated markets of North America...
Load More
